

Vimta Labs Limited

Registered Office
142, IDA Phase II, Cherlapally
Hyderabad-500 051, Telangana, India
T : +91 40 2726 4141
F : +91 40 2726 3657



VLL\SE\083\2025-26
Date: 28.01.2026

B S E Limited, P J Towers, Dalal Street, Mumbai - 400001. Scrip Code : 524394	National Stock Exchange of India Limited, "Exchange Plaza", Bandra, Kurla Complex, Bandra (E), Mumbai – 400051. Trading Symbol: VIMTALABS
--	--

Dear Sir/Madam,

Sub – Press Release – Unaudited Financial Results – 31st December 2025.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, please find attached the press release regarding the announcement of the unaudited Financial Results for the 3rd Quarter and Nine Months ended 31st December 2025.

This is for your information and records.

Thanking you,

For VIMTA LABS LIMITED

Sujani Vasireddi
Company Secretary



Encl: as above.

Vimta Labs Limited Reports Q3 & 9M FY26 Results

Q3 FY26 Total Income reported at Rs. 1,005 Mn, up 10.2% YoY
EBITDA margins at 34.3%; PAT margin at 17.5%

Hyderabad, January 28, 2026: Vimta Labs Limited (VIMTA) (BSE: 524394, NSE: VIMTALABS), India's leading Contract Research and Testing Organisation, has announced its financial results for the quarter and nine month ended December 31, 2025.

Financial Results – Q3 & 9M FY26:

Particulars (Rs. Mn)	Q3 FY26	Q2 FY26	QoQ(%)	Q3 FY25	YoY (%)	9M FY26	9M FY25	YoY (%)
Total Income	1,005	1,045	-3.9%	911	10.2%	3,043	2,521	20.7%
EBITDA (including other income)	344	369	-6.6%	343	0.4%	1,068	915	16.7%
EBITDA Margin	34.3%	35.3%		37.6%		35.1%	36.3%	
PAT (continued operations)	176	199	-11.7%	175	0.4%	564	484	16.4%
PAT Margin	17.5%	19.1%		19.2%		18.5%	19.2%	
Basic EPS	4.0	4.5	-11.2%	3.9	0.8%	12.7	10.9	16.2%

Note: Vimta Labs sold its Diagnostic and Pathological services business to Thyrocare Technologies, as announced on August 30, 2024, with the transfer completed on October 11, 2024. Previous period figures for P&L have been regrouped to ensure comparability with the current period

Commenting on results, Ms. Harita Vasireddi, Managing Director, Vimta Labs Limited, said:

"I am pleased to share that this quarter has been a positive one for Vimta Labs, with total income of ₹1,005 mn, reflecting a YoY growth of 10.2%. This performance underscores our continued focus on excellence in scientific research, operational discipline, and customer trust. Strong demand across our service offerings, coupled with improved operational efficiencies, has resulted in healthy growth and resilient EBITDA margins of 34.3% (after considering Exceptional item – New Labour Codes impact). Our teams have demonstrated exceptional commitment to quality, enabling us to further strengthen Vimta's position as a preferred partner for both regulated and emerging markets. Looking ahead, we remain confident in our strategic direction and will continue to invest in capabilities that enhance long-term value for our clients, stakeholders, and the broader people wellness ecosystem."

Key Result Highlights for the Q3 & 9M FY26:

Q3 FY26

- ✓ Total Income for Q3 FY26 was at Rs. 1,005 Mn
- ✓ EBITDA for Q3 FY26 was Rs. 344 Mn; EBITDA margin was at 34.3%
- ✓ PBT for Q3 FY26 was at Rs. 234 Mn
- ✓ Q3 FY26 PAT was at Rs. 176 Mn; PAT margin was at 17.5%
- ✓ Basic EPS in Q3 FY26 was Rs. 3.96

9M FY26

- ✓ Total Income for 9M FY26 was at Rs. 3,043 Mn
- ✓ EBITDA for 9M FY26 was Rs. 1,068 Mn; EBITDA margin was at 35.1%
- ✓ PBT for 9M FY26 was at Rs. 749 Mn
- ✓ 9M FY26 PAT was at Rs. 564 Mn; PAT margin was at 18.5%
- ✓ Basic EPS in 9M FY26 was Rs. 12.67

Note:

Vimta Labs sold its Diagnostic and Pathological services business to Thyrocare Technologies, as announced on August 30, 2024, with the transfer completed on October 11, 2024. Previous period figures for P&L have been regrouped to ensure comparability with the current period.

ABOUT VIMTA LABS LIMITED:

Founded in 1984 with headquarters in Hyderabad, India, VIMTA LABS LTD., is a leading contract research and testing organization, providing food, agri, bio/pharmaceutical, medical device, speciality chemical, and electronics companies an integrated scientific, technical, and regulatory expertise to support all stages of product development and manufacturing process. Vimta also provides environmental assessments and testing services.

CAUTIONARY STATEMENT:

This press release may contain certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward-looking statements. No warranties or representations are made as to the accuracy, achievement, or reasonableness of such statements, estimates or projections, and Vimta Labs Limited has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.

For details, please contact:

Investor Relations at Vimta Labs Siva Kambhampati (Chief Financial Officer) Siva.Kambhampati@Vimta.com Ernst & Young Siddesh Chawan Siddesh.Chawan@in.ey.com Advait Bhadekar Advait.bhadekar@in.ey.com	Registered Office Plot Number 142, IDA Phase 2, Cherlapally, Hyderabad Telangana, India. 500051 CIN: L24110TG1990PLC011977 ISIN: INE579C01029 NSE Code: VIMTALABS BSE CODE: 524394 Website: www.vimta.com
---	--